exp3174 has been researched along with Arrhythmia in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Gould, RJ; Grossman, W; Kusma, SE; Lynch, JJ; Painter, CA; Stump, GL; Thomas, JM; Wallace, AA | 1 |
1 other study(ies) available for exp3174 and Arrhythmia
Article | Year |
---|---|
EXP3174, the AII antagonist human metabolite of losartan, but not losartan nor the angiotensin-converting enzyme inhibitor captopril, prevents the development of lethal ischemic ventricular arrhythmias in a canine model of recent myocardial infarction.
Topics: Analysis of Variance; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Captopril; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Female; Heart Ventricles; Humans; Imidazoles; Losartan; Male; Myocardial Infarction; Myocardial Ischemia; Tetrazoles; Time Factors | 1999 |